Clinical Trials Logo
  1. Home
  2. Metabolic Acidosis
  3. NCT05147051

Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

Metabolic Acidosis Clinical Trial

Official title:
Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of REAMBERIN® (Meglumine Sodium Succinate) Used for Correction of Metabolic Acidosis in Critically Ill Patients

Clinical Trial Summary

An acid-base imbalance, called metabolic acidosis (acid-base disorder lasting from several minutes to several days, caused by a decrease in serum bicarbonate ion (HCO3) concentration), is often observed in critically ill patients with various underlying diseases. Metabolic acidosis has a negative impact on the cardiovascular, respiratory, digestive, nervous, excretory, hematological, endocrine, musculoskeletal and immune systems and is associated with unfavourable outcomes. Reamberin® is a solution of disubstituted sodium salt of succinic acid, which has an alkaline reaction and succinate is capable to integrate into the Krebs cycle and restore energy metabolism in the cell. The aim of the present study is to evaluate the efficacy and safety of meglumine sodium succinate at a dose of 500 to 3000 ml in critically ill patients with metabolic acidosis and choose the optimal volume of its solution for the correction of metabolic acidosis in critically ill patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05147051
Study type Interventional
Source POLYSAN Scientific & Technological Pharmaceutical Company
Contact
Status Completed
Phase Phase 2
Start date June 16, 2021
Completion date June 22, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Completed NCT03317444 - Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Recruiting NCT05582824 - Lactate Metabolism in the Hypoperfused Critically Ill
Active, not recruiting NCT04010630 - Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU N/A
Completed NCT02303548 - Bicarbonate in Patients With Out-of-hospital Cardiac Arrest Phase 2
Recruiting NCT01860001 - Incidence of Postoperative Ketosis and Metabolic Acidosis N/A
Completed NCT01452412 - Alkali Therapy in Chronic Kidney Disease Phase 2/Phase 3
Terminated NCT03710291 - Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis Phase 3
Recruiting NCT02476253 - Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill Phase 3
Completed NCT05940935 - The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations
Withdrawn NCT03846258 - High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy Phase 4
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Terminated NCT04727528 - Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Completed NCT02098356 - Comparison of High Versus Low Bicarbonate Hemodialysis N/A
Recruiting NCT03897101 - Inflammation and Metabolic Acidosis at Birth (AGAIN: AutophaGy AcIdosis Newborn)
Terminated NCT01894594 - Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease Phase 1
Completed NCT01075750 - Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants N/A
Completed NCT01295190 - Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass N/A
Completed NCT01293266 - Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation N/A